




Universal Biosensors

Universal Biosensors: Investor presentation

September 2009

Disruptive innovation at the point of care to create new markets and opportunities



Important disclaimer

- This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. This presentation is not financial advice and has been prepared without taking into account the objectives, financial situation or needs of a particular person.
- Neither the Company, nor its officers or advisors or any other person warrants the accuracy of the analysis herein or guarantees the investment performance of the Company. Investors must make their own independent assessment of the Company and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes.
- Under applicable United States securities laws all of the shares of our common stock are “restricted securities” as that term is defined in Rule 144 under the Securities Act of 1933, as amended (**Securities Act**). Restricted securities may be resold in the public market to United States persons as defined in Regulation S only if registered for resale or if they qualify for an exemption from registration under the Securities Act. We have not agreed to register any of our common stock for resale by security holders.
- The statements contained in this presentation that are not purely historical are forward-looking statements within the meaning of the Exchange Act. Forward-looking statements in this presentation include statements regarding our expectations, beliefs, hopes, intentions or strategies regarding the proposed offering. All forward-looking statements included in this presentation are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations.
- The Company is subject to a number of risks. For a summary of key risks, refer to the Company’s most recent Form10-K filed with the United States Securities and Exchange Commission.



Universal Biosensors – GMP facility



Universal Biosensors

Universal Biosensors – transformational manufacturing



Universal Biosensors

UBI and LifeScan (blood glucose/diabetes) – a strong relationship

- 2002 Licence Agreement
- 2002 Development and Research Agreement
- 2003 Johnson and Johnson Development Corporation equity investment
- 2007 Master Services and Supply Agreement (MSSA)
- 2008 Fee for Service (scale up tasks)
- 2008 Manufacturing Process Support Agreement (2008)
- 2009 MSSA updated
- 2009 Development and Research Agreement updated
- 2010 UBI is preparing for a LifeScan launch of a first product



Income streams to UBI from the MSSA

- The Master Services and Supply Agreement:
 - Umbrella agreement permitting multiple products
 - UBI provides services and is a (non-exclusive) manufacturer of sensor strips
 - UBI anticipates developing other products for LifeScan
- For the product pending:
 - Milestone payable on regulatory approval
 - Price per strip manufactured by us and sold to LifeScan
 - Additional service fee calculated based on the number of strips sold to consumers, regardless of who in the future has manufactured the strips
 - ~A\$25m UBI revenue forecast in the 12 months from regulatory approval



First blood glucose product



- Enhanced product could be registered as early as H2 2009
- UBI is production ready
- LifeScan controls the timing of regulatory submissions
- LifeScan chooses place and time of market entries



Universal Biosensors

A holy grail realised?

Immunoassay and other finger prick measurements as simply and easily as a blood glucose test




Protected - extensive licenced and owned IP

- 39 patent families covering products, manufacturing, core and peripheral technology
- 244 granted patents
- 171 pending applications
- 415 patents plus applications




Universal Biosensors

At the heart of the Universal Biosensors platform, transformational technology



Universal Biosensors

At the heart of the Universal Biosensors platform, transformational technology



Universal Biosensors

Systematic Extension of Platform Value

- Platform
 - Enzyme-substrate (small molecules e.g. blood glucose)
 - Immunoassay (proteins, peptides e.g C-reactive protein, D-Dimer)
 - Coagulation (prothrombin time; other clot based tests feasible)
 - RNA/DNA application foreshadowed



Sophisticated, simple, unique

UBI point of care (POC) tests developed by UBI use a dry, single use biosensor strip to measure biomarkers in a finger prick blood sample. Measurements made by a hand-held, battery powered, microprocessor controlled meter are converted to a reading.



The patient or other user inserts a test strip into the meter and after the finger is pricked, touches the tiny drop to the biosensor strip

The resulting reaction within the electrochemical cell is measured electronically by the meter

It is possible to respond to the result within seconds or minutes



Universal Biosensors

Results “here and now” permit better, safer medicine




Product pipeline

	APPLY CORE TECHNOLOGY: OPPOSED ELECTRODES, ALGORITHM, WEB BASED MANUFACTURE	PROTO-TYPE	DEVELOPMENT CYCLE	PRODUCTION CAPABILITY/ CAPACITY	MARKET REACH	MARKET LAUNCH	MARKET EXPANSION
Blood Glucose						Specification change 2/09	
Enhanced Blood Glucose Product						2010	
C-Reactive Protein				CURRENTLY DESIGNING	NEGOTIATE Starting 2009	2011 →	
Prothrombin Time				CURRENTLY DESIGNING	NEGOTIATE Starting 2009	2010	2011 →
D-Dimer				CURRENTLY DESIGNING	NEGOTIATE Starting 2009	2011	2012 →

hsCRP: A Powerful Multi-Purpose Biomarker

- Systemic inflammation underlies much chronic disease
- Across a range of therapeutic areas, C-reactive protein (*hsCRP*) elevates in the presence of key inflammatory cytokines
- Diseases with a disturbed inflammatory axis include atherosclerosis, rheumatoid arthritis and other autoimmune diseases, cancer, COPD and Alzheimer's disease




On blood thinners for life (Prothrombin Time)

- In the safe zone?
- How and when do you know?
- Can current practice be improved?




Market size

In Vitro Diagnostic Market



Point-of-Care Testing Market (US\$m)



Worldwide Market	Estimated Market Size in 2005	Forecast Market Size in 2010
<i>In vitro</i> diagnostic testing	US\$32.2 bn	US\$45.5 bn
Point-of-care testing (POC)	US\$11.1 bn	US\$16.2 bn



Universal Biosensors

Key messages

- Innovator
 - Market opportunity within current healthcare structure and within future system, whatever the shape
 - Transformational manufacturer
 - A true flexible, decentralized POC platform on its way to multiple products
- Superb execution to date
 - LifeScan relationship (a J&J company)
 - Close to market



Universal Biosensors

Corporate summary

Summary

Number of Shares on issue 157,038,558

Market capitalization at 21 September 2009 ~A\$208.9 million

Number of Options on issue 8,495,527

Cash (at August 31, 2009) ~A\$19.1 million

Board of Directors

Mark Morrisson (CEO), Andrew Denver (Chairman), Colin Adam, Denis Hanley, Andrew Jane, Charles Kiefel, Jane Wilson



Universal Biosensors